Lenz Therapeutics: Raises $47M in Series A Financing

Lenz Therapeutics Raises $47M in Series A Financing

• Lenz Therapeutics, a San Diego, CA-based biopharmaceutical company, raised $47m in Series A funding
• Backers included Versant Ventures and RA Capital Management
• The company intends to use the funds to progress its lead asset, an eyedrop formulation of aceclidine, towards an NDA submission for the treatment of presbyopia
• The company is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision
• Its lead program, aceclidine, is an eye drop designed to restore the loss of near vision associated with presbyopia
• Aceclidine is an NCE in the U.S. and has an established safety profile from its prior use in Europe for glaucoma